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Proteomic analysis reveals GIT1
as a novel mTOR complex
component critical for
mediating astrocyte survival
Laura J. Smithson and David H. Gutmann
Department of Neurology, Washington University School of
Medicine, St. Louis, Missouri 63110, USA

As a critical regulator of cell growth, the mechanistic target of rapamycin (mTOR) protein operates as part of two
molecularly and functionally distinct complexes. Herein,
we demonstrate that mTOR complex molecular composition varies in different somatic tissues. In astrocytes
and neural stem cells, we identified G-protein-coupled
receptor kinase-interacting protein 1 (GIT1) as a novel
mTOR-binding protein, creating a unique mTOR complex lacking Raptor and Rictor. Moreover, GIT1 binding
to mTOR is regulated by AKT activation and is essential
for mTOR-mediated astrocyte survival. Together, these
data reveal that mTOR complex function is partly dictated by its molecuflar composition in different cell types.
Supplemental material is available for this article.
Received February 16, 2016; revised version accepted
May 16, 2016.

Eukaryotic cell growth relies on the precise coordination
and control by the highly conserved serine/threonine
protein kinase mechanistic target of rapamycin (mTOR).
In response to growth factors, amino acids, oxygen levels,
and stress, mTOR assembles into two functionally and
molecularly distinct multiprotein complexes to regulate
a variety of diverse growth-related cellular processes, including mRNA translation (Barbet et al. 1996), ribosomal
biogenesis, transcription (Mayer et al. 2004), cell cycle
progression (Fingar et al. 2004), survival (Paglin et al.
2005), and cytoskeletal dynamics (Jacinto et al. 2004; Sarbassov et al. 2004).
Based on studies in mouse embryonic fibroblasts and
nonneural cell lines (HEK293 cells), mTOR has been
shown to interact with either Raptor and the proline-rich
AKT substrate of 40 kDa (PRAS40) to form mTOR complex 1 (mTORC1) or Rictor and the mammalian stressactivated map kinase interacting protein 1 (mSIN1) to generate mTORC2 (Kim et al. 2002; Sarbassov et al. 2004;
Jacinto et al. 2006; Oshiro et al. 2007). As such, mTORC1
function is critical for the regulation of transcription and
protein translation through phosphorylation of p70-S6
kinase 1 (S6K1) and eukaryotic translation initiation factor 4E (elF4E)-binding protein 1 (4-EBP1) (Gingras et al.
1998; Hara et al. 1998). In contrast, mTORC2 controls actin cytoskeleton dynamics and cell survival by signaling
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to protein kinase C-α (PKCα), protein kinase B (AKT),
and serum- and glucocorticoid-induced protein kinase 1
(SGK1). Beyond these protein interactors, other mTORbinding proteins have been identified, including DEP
domain-containing mTOR-interacting protein (Deptor),
mammalian lethal with SEC13 protein 8 (mLST8), and
protein observed with Rictor (Protor), each with varying
capacities to influence mTOR-dependent function (Kim
et al. 2003; Peterson et al. 2009). While the roles of these
other mTOR complex molecules in cell growth have not
been fully elucidated, it is clear that the mTOR complex
is a central regulator of normal cell biology.
The importance of mTOR function to normal development and maintenance is underscored by the identification of mutations in genes encoding proteins that negatively regulate mTOR as causative etiologies for several
human neurological diseases, including Neurofibromatosis type 1 (NF1), Cowden’s syndrome (PTEN), and tuberous sclerosis complex (TSC). In these disorders, loss of
function of neurofibromin (NF1), PTEN, and tuberin/
hamartin (TSC) lead to mTOR hyperactivation and increased cell growth. While each of these proteins negatively regulates mTOR function, the biological consequences
are distinct. First, the mechanisms underlying tuberin/
hamartin and neurofibromin mTOR suppression are separable and reflect different modes of mTOR activation
(Banerjee et al. 2011). As such, Nf1 loss in astrocytes leads
to increased proliferation, whereas Tsc1 loss has no effect
on astrocyte proliferation but results in increased cell size
(Uhlmann et al. 2004). Second, mTOR controls proliferation distinctly in different cell types. While Tsc1 loss
increases mTOR activation and cell growth in fibroblasts,
it has no effect on astrocyte proliferation despite increased
mTOR activation (Sandsmark et al. 2007; Banerjee
et al. 2010). Third, the composition and function of the
mTOR complex is partly dictated by tissue-specific
constraints. For example, the ability of brainstem, but
not cortical, neural stem cells (NSCs) to increase their proliferation and glial cell differentiation following Nf1 gene
inactivation reflects a fivefold increase in Rictor expression in brainstem NSCs relative to their cortical counterparts (Lee da et al. 2010).
In light of these findings, we sought to define the molecular composition and function of the mTOR complex in
the brain. Leveraging a combination of proteomic, genetic, and pharmacological approaches, we identified a novel
AKT-regulated mTOR complex protein (G-protein-coupled receptor kinase-interacting protein 1 [GIT1]) in brain
tissues whose function is essential for mTOR-mediated
astrocyte survival.
Results and Discussion
To characterize the mTOR complex in brain cells, we focused on astrocytes, since these cells represent the nonmalignant counterpart of the cancer cells in the most
common brain tumor (astrocytoma or glioma). Western
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blotting of whole-cell lysates from wild-type brainstem
astrocytes demonstrated cell type differences in the
expression of known mTOR-binding proteins (Fig. 1A).
While Rictor, Raptor, mSIN1, PRAS40, and mLST8 were
expressed in human HEK293 cells, mouse astrocytes,
and mouse fibroblasts, there was an absence of both Deptor and Protor-1 expression in wild-type mouse astrocytes
and fibroblasts (Supplemental Fig. S1A).
Next, to determine whether the known mTOR-binding
proteins were contained in the mTOR complex in nervous system cells, mTOR immunoprecipitation was performed. As observed in other cell types, Rictor, Raptor,
mSIN1, PRAS40, and mLST8 were found in mTOR complexes in mouse astrocytes (Fig. 1B), similar to fibroblasts
(Fig. 1C). Since there are two functionally distinct mTOR
complexes, identified by their expression of Raptor and
PRAS40 (mTORC1) or Rictor and mSIN1 (mTORC2), we
performed Raptor and Rictor immunoprecipitations. As
observed in other cell types, both the mTORC1 complex
(Raptor, PRAS40, and mLST8) and the mTORC2 complex
(Rictor, mSIN1, and mLST8) were identified in mouse
astrocytes (Fig. 1D).
To identify potential novel astrocyte-specific mTORbinding proteins, we performed proteomic analyses on
mTOR immunoprecipitations from wild-type astrocytes.
Using a spectral abundance score of ≥10 (and a spectral
count for nonspecific rabbit IgG = 0) and excluding
known nonspecific binding proteins (Mellacheruvu et al.
2013; Contaminant Repository for Affinity Purification,
http://141.214.172.226, version 1.1), three mTOR-binding
protein candidates were identified (Fig. 2A). Using independently prepared mTOR immunoprecipitations, only
endogenous GIT1–mTOR binding was validated (Fig.
2B). Importantly, mTOR was contained in GIT1 immunoprecipitations (Fig. 2C), and mTOR and GIT1 binding
was observed in HEK293T (293T) cells transfected with
myc-mTOR and Flag-GIT1 (Fig. 2D). We also identified
a known GIT1-binding protein, Rho guanine nucleotide
exchange factor 7 (also called PAK-interacting exchange
factor (β-PIX) (Bagrodia et al. 1999; Zhao et al. 2000), in

Figure 1. mTOR complex composition is cell type-specific. (A) Representative immunoblots demonstrate little Deptor and Protor-1 expression in wild-type mouse astrocytes and fibroblasts relative to HEK293T
(293T) cells. Immunoblots from mTOR immunoprecipitations reveal
Rictor, Raptor, mSIN1, PRAS40, and mLST8 in wild-type astrocytes
(B) and fibroblasts (C ). Rb IgG was included as an internal control for
nonspecific binding. (D) While Raptor (mTORC1) immunoprecipitations contained mTOR, Raptor, PRAS40, and mLST8 (but not Rictor),
Rictor (mTORC2) immunoprecipitations contained mSIN1 and
mLST8 but lacked Raptor and PRAS40 in wild-type astrocytes.
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mTOR immunoprecipitations (spectral abundance score
= 9), which was subsequently confirmed by immunoprecipitation (Supplemental Fig. S2A).
To determine whether the interaction between GIT1
and mTOR was neural cell-specific, GIT1 binding to
mTOR was examined in whole-mouse brainstem tissues,
mouse brainstem NSCs, mouse Nf1 −/−; p53 −/− NPcis
glioma cells, and 293T cells. GIT1 was expressed and
binds mTOR in 1-d-old (postnatal day 1 [P1]) and 1-moold mouse brainstem tissues (Supplemental Fig. S2B),
NSCs, and NPcis glioma cells (data not shown) as well
as in 293T cells, albeit at 100-fold reduced levels (Supplemental Fig. S2C). In this regard, GIT1 was predominately
expressed in the brain (the cortex, cerebellum, and olfactory bulb) relative to nonneural tissues (the liver, kidney,
and heart) (Supplemental Fig. S2D).
Next, to ascertain whether GIT1 was contained in the
mTORC1 or C2 complex, Raptor (mTORC1) and Rictor
(mTORC2) immunoprecipitations were performed. While
mTOR and mLST8 were contained in both Raptor and
Rictor immunoprecipitations, GIT1 was not found in
either mTOR complex (Fig. 2E), and Raptor and Rictor
were not found in GIT1 immunoprecipitations. Furthermore, mSIN1 and PRAS40 were also not found in
GIT immunoprecipitations (Supplemental Fig. S2E).
These data demonstrate that GIT1 is not a component
of either of the two established mTOR complexes and
likely belongs to a newly identified mTOR complex containing GIT1 and β-PIX (but lacking Raptor, Rictor,
mSin1, PRAS40, and mLST8).
To identify GIT1 residues important for mTOR binding,
293T cells were transfected with full-length epitopetagged mTOR and GIT1 deletion constructs. Following
myc-mTOR immunoprecipitation, full-length GIT1 and
GIT1 fragments containing residues 250–770 or 420–770
as well as the deletion mutant missing residues 264–430
(delSHD) bound mTOR (Fig. 2F). In contrast, GIT1 containing residues 1–420 did not associate with mTOR, demonstrating that GIT1 binding to mTOR requires GIT1
residues 420–770, encompassing the synaptic localization
domain (SLD) and paxillin-binding domain (PBD). Finally,
to define the mTOR residues critical for GIT1 binding,
293T cells were transduced with epitope-tagged fulllength GIT1 and mTOR deletion fragments. mTOR fragments containing residues 1271–2008 and 1750–2549,
but not residues 1–1482, bound GIT1 (Fig. 2G), demonstrating that GIT1 binds mTOR between residues 1482 and
2008 within the FRAP, ATM, and TRAP (FAT) domain.
To determine how GIT1 binding to mTOR is regulated,
we focused on one tumor suppressor protein that operates
through the mTOR pathway and is essential for glioma
pathogenesis. The NF1 protein neurofibromin suppresses
astroglial growth by inhibiting RAS activation of AKTmediated mTOR signaling (Sandsmark et al. 2007; Banerjee et al. 2011; Kaul et al. 2015) such that neurofibromin
loss results in increased (1.7-fold) astrocyte proliferation
and S6 (phospho-S6Ser240/244; 2.2-fold) activation (Fig.
3A). In Nf1 −/− astrocytes, there was a 2.5-fold decrease
in GIT1 binding to mTOR relative to wild-type astrocytes
(Fig. 3A). Since GIT1 binding to mTOR requires residues
420–770, containing a putative phosphorylation residue
(Tyr544), GIT1 phosphorylation was examined. No change
in GIT1Tyr544 phosphorylation was observed following
Nf1 loss (Supplemental Fig. S3A), excluding this residue
as the regulatory phosphorylation site responsible for
GIT1 binding to mTOR.
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since AKT regulates GIT1 binding to
mTOR, we sought to determine
whether two mTOR phosphorylation
sites (Ser2448 and Ser2481) (Peterson
et al. 2000; Sekulic et al. 2000) were
regulated by mTOR/AKT activation.
No changes in mTOR Ser2448 and
Ser2481 phosphorylation were observed in Nf1 −/− astrocytes relative
to their wild-type counterparts (Supplemental Fig. S3B), excluding this potential mechanism. However, it is
possible that other phosphorylation
sites exist for which antibodies are
currently unavailable.
To determine whether GIT1 is required for neurofibromin-mediated astrocyte growth, three independently
generated
mouse-specific
Git1
shRNA (shGit1) constructs were evaluated, and the two with the greatest
knockdown in wild-type (3.1-fold and
3.5-fold reduction) and Nf1 −/− (2.5fold and 2.1-fold reduction) astrocytes
were selected (Fig. 4A). Following
shGit1 knockdown, Nf1 −/− astrocyte
growth was reduced to wild-type levels, with no effect on wild-type astrocytes (Fig. 4B; Supplemental Fig. 4A).
This reduction in cell growth was the
result of increased cell death (apoptosis), as revealed by an increase in cleaved caspase-3 levels (Supplemental
Figure 2. GIT1 is a novel mTOR-binding protein in astrocytes. (A) Proteomic analysis of mTOR
Fig. S4B) and the percentage of
immunoprecipitations from wild-type astrocytes reveals several potential mTOR-binding proTUNEL+ astrocytes (Fig. 4C). No
teins. (B) Validation of mTOR-binding proteins with spectral counts of ≥10 by immunoblot rechange in LC3A/B expression (autophveals that endogenous GIT1, but not TGM2 or RhoC, associates with mTOR. Rb IgG was
included as an internal control for nonspecific binding. (C ) GIT1 and mTOR binding is also obagy) was observed (Supplemental Fig.
served in GIT1 immunoprecipitations from wild-type astrocytes. (D) Full-length Flag-tagged
S4B). As before, no change in cleaved
GIT1 (Flag-GIT1) and myc-tagged mTOR (myc-mTOR) associate in HEK293 cells. Flag-pCMVg
caspase-3 levels or the percentage of
(empty vector) was used as a control. (E) GIT1 is not found in Raptor (mTORC1) or Rictor
TUNEL+ cells was observed following
(mTORC2) immunoprecipitations by immunoblot. Raptor, Rictor, and mLST8 are not conshGit1
knockdown in wild-type astrotained in GIT1 immunoprecipitations. (F) Full-length myc-mTOR binding to Flag-GIT1 requires
GIT1 residues 420–770 (dotted outline) containing the paxillin-binding domain (PBD) and a porcytes (Supplemental Fig. S4C).
tion of the synaptic localization domain (SLD). ANK denotes the ankyrin repeats, while SHD deGIT1 was initially identified as a Gnotes the Spa2 homology domain. (G) Full-length Flag-GIT1 binding to myc-mTOR requires
protein-coupled receptor kinase 2mTOR residues 1482–2008, encompassing the mTOR FRAP, ATM, and TRAP (FAT) domains.
binding protein (Premont et al. 1998)
and has been implicated in the control
of receptor trafficking, protein comBecause neurofibromin controls mTOR function in an
plex assembly/transport, focal adhesion turnover, synapse
AKT-dependent manner, the impact of its inhibition
formation, cell motility, and cell growth (Zhao et al. 2000;
on GIT1/mTOR binding was assessed. First, GIT1 binding
Manabe et al. 2002; Za et al. 2006). GIT1 can also act as a
to mTOR was increased following treatment with 10 nM
GTPase-activating protein for the ADP ribosylation factor
rapamycin (2.5-fold) (Fig. 3B), suggesting that conformafamily of small GTPases (Claing et al. 2000; Vitale et al.
tional changes in mTOR resulting from rapamycin/
2000), including Rac1 (Zhang et al. 2005; Chang et al.
FKBP12 binding to the adjacent FRB domain might be re2015), by binding to the C-terminal region of the Rho guasponsible for this effect. Second, pharmacological AKT innine nucleotide exchange factor 7 (ARHGEF7 or β-PIX)
hibition (50 nM MK2206) decreased mTOR (S6Ser240/244
and promoting the interaction of β-PIX with Rac1 (Bagrophosphorylation) and AKT (AKTThr308, PRAS40Thr246,
dia et al. 1999; Zhang et al. 2005; Fiuza et al. 2013). Howand GSK-3βSer9 phosphorylation) activation in Nf1 −/− asever, we observed no reproducible changes in Rac1
trocytes (Fig. 3C) and also resulted in increased (3.9-fold)
activity following shGit1 knockdown (Supplemental Fig.
GIT1 binding to mTOR, establishing that GIT1 binding
S4D), and β-PIX knockdown did not alter Nf1 −/− astrocyte
proliferation (data not shown). In addition, GIT1 has been
to mTOR is mediated by AKT/mTOR activation. This
implicated as a Hippo pathway regulator; however, no
increase in GIT1 binding to mTOR following AKT inhichange in YAP levels or YAP phosphorylation (Ser137)
bition was not observed in wild-type astrocytes (Supwas observed in Nf1-deficient astrocytes before or after
plemental Fig. S3C). Importantly, no change in GIT1/
mTOR binding was observed following MEK inhibition
shGit1 knockdown (Supplemental Fig. S4E). Since GIT1
is an mTOR-binding protein, it is possible that reduced
(PD901) (data not shown) in Nf1 −/− astrocytes. Third,
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sults obtained when studying mTOR
in different tissue types or cell populations. Second, mTOR function is also
dictated by the formation of at least
two functional complexes containing
distinct binding partners. While two
distinct mTOR complexes (mTORC1
and mTORC2) were identified in astrocytes, we describe for the first
time the existence of a third mTOR
complex composed of GIT1 and βPIX but not Rictor or Raptor. Support
for additional mTOR complexes derives from studies examining oxygeninduced mTOR-mediated translational activation of terminal oligopyrimidine (TOP) mRNA in fibroblasts
(Miloslavski et al. 2014), where
mTOR regulation of TOP mRNA
translation was independent of Rictor
or Raptor and occurred in the absence
of S6K and 4EBPI activation. Additionally, rapamycin inhibition of mSin1
phosphorylation in human rhabdomyosarcoma cells was mimicked by
mTOR or mLST8 silencing but not
Figure 3. Neurofibromin loss decreases GIT1 binding to mTOR. (A) Neurofibromin loss results
by Raptor, Rictor, S6K1, or AKT loss
S240/244
in increased astrocyte growth and mTOR activation (phospho-S6
) relative to wild-type
(Luo et al. 2015), suggesting the prescontrols. Reduced GIT1 binding to mTOR is observed in Nf1 −/− relative to wild-type astrocytes.
ence of a new mTOR complex conScatter plots illustrate independently generated mTOR immunoprecipitations. Treatment with
taining only mSIN1 and mLST8.
the either 10 nM rapamycin (B) or 50 nM MK2206 (C) increases GIT1 binding to mTOR in Nf1 −/−
astrocytes. mTOR and AKT inhibition were confirmed by decreased S6 (phospho-S6Ser240/244),
Third, mTOR function can be regulatAKT (phospho-AKTThr308), PRAS40 (phospho-PRAS40Thr246), and GSK-3β (phospho-GSKed by different upstream modulators.
Ser9
∗
∗∗
3β ) phosphorylation. ( ) P < 0.05; ( ) P < 0.005.
As such, we showed previously that
Pten and neurofibromin loss have simGIT1–mTOR association results in either increased Rapilar effects on mTOR activation and proliferation in astrotor (C1) or Rictor (C2) binding to mTOR or increased
cytes, whereas tuberin/hamartin loss activates mTOR
mTORC1/C2 effector activation. However, there was no
through Rheb and does not result in increased astrocyte
change in Raptor or Rictor binding to mTOR following
growth (Banerjee et al. 2011). Moreover, Nf1 +/− mice
with somatic Nf1 gene inactivation in astroglial progeniNf1 loss/AKT activation (Fig. 3A), and no changes in the
tors develop optic gliomas, whereas Nf1 +/− mice with
activation of known mTORC1 (4EBP1) or mTORC2
Rheb expression in astroglial progenitors do not develop
(SGK1 and PKCα/β-II) effectors were observed before or after shGit1 knockdown in Nf1-deficient astrocytes (Supoptic gliomas despite robust mTOR hyperactivation.
In summary, these studies establish that the molecular
plemental Fig. S4E). Collectively, the findings reported
composition and function of mTOR can be cell type-spehere suggest that GIT1/mTOR binding likely sequesters
cific and identify a novel mTOR complex critical for astroGIT1 from activating its currently unidentified downcyte survival. These findings have important implications
stream effectors to mediate astrocyte survival (Fig. 4E).
for the interpretation of future mTOR functional studies
Future studies will be required to identify these signaling
in distinct tissues relevant to the design and execution
intermediates.
of clinical therapeutic trials that target mTOR function
Taken together, the identification of a new GIT1/
mTOR complex in this study raises several important
in specific organs.
points relevant to mTOR composition and function. First,
mTOR creates a level of functional diversity by interactMaterials and methods
ing with unique binding partners in different tissue types.
In this regard, we reported previously that mTOR comMice
plex composition and function in NSCs are dictated by
Nf1 flox/flox (wild-type) mice were generated and maintained as previously
brain region-specific differences in Rictor expression
described (Zhu et al. 2001; Bajenaru et al. 2002). Mice were used in strict
(Lee da et al. 2010). Similarly, while Deptor regulates
accordance with an approved animal studies protocol at the Washington
mTOR kinase activity in HEK293 cells, it is not expressed
University School of Medicine.
in wild-type mouse astrocytes and fibroblasts. Loss of Protor-1 expression decreases N-myc downstream-regulated
gene-1 (NDRG1; mTORC2 effector) activation in the kidCell culture
ney but not in the brain (Pearce et al. 2011). As such, the
Wild-type and Nf1-deficient (Nf1 −/−) astrocytes were generated from the
differential expression of mTOR-interacting proteins
brainstems of P1–P2 mouse pups, and Nf1 gene inactivation was perin various tissues and species (Pearce et al. 2011; Yuan
formed using adenovirus type 5 (Ad5) (University of Iowa Gene Transfer
et al. 2015) or cell lines (Sarbassov et al. 2004; Foster
Vector Core, Iowa City, IA) as previously described (Sandsmark et al.
et al. 2010) may partly explain potentially conflicting re2007). Fibroblasts were prepared from small ear sections from P1–P2
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rabbit IgG (Rb IgG; control) and immunoprecipitated using protein G
beads. Bead/protein complexes were washed three times with 0.3%
CHAPS buffer containing 120 mM NaCl2 and eluted in 2× Laemmli buffer
prior to Western blot analysis. Rapamycin (10 nM) was included during the
immunoprecipitation incubation step to inhibit mTOR. For 293T cells,
mTOR immunoprecipitations were performed using 600–800 µg of input
protein with and without fetal bovine serum (FBS).

Proteomic analysis
Precleared lysates (1.3 mg) from wild-type astrocytes were processed for
immunoprecipitation as described above. Flash-frozen elutes were separated by SDS-PAGE on 10% Bis-Tris NuPAGE gels (Invitrogen) and processed
by in-gel digestion with trypsin at 37°C for analysis by nanoscale liquid
chromatography coupled to tandem mass spectrometry (MS Bioworks).
Resulting peptides were identified using Mascot and filtered using a 1%
protein and peptide false discovery rate and requiring at least two unique
peptides per protein. Peptides are listed by descending spectral counts
(protein abundance) with their accession number and molecular weight
(Supplemental Table S3).

Viral production
293T cells were transfected with 10 µg of each protein fragment (Supplemental Table S2; Yin et al. 2004) in Opti-MEM (Gibco) using X-tremeGENE 9 (Roche). Mouse-specific Git1 shRNAi lentiviral constructs
(shGit1) (Sigma Mission, TRCN0000346581 and TRC0000346504) were
generated following 293T Fugene HD-mediated transfection with 10 µg
of shGit1, 5 µg of pMD1, 2.5 µg of Rev, and 3 µg of pCMVg (Supplemental
Table S2). Filtered virus was applied to astrocytes in 0.6 µL/mL Polybrene
(Millipore). pLKO-anti-GFP lentivirus was used as a control.

Pharmacological inhibitors
Cells were treated in serum-free medium with 10 nM rapamycin (LC Laboratories), 50 nM MK2206 (Selleck), or 1 nM PD901 (Selleck) for 18 h (for
proliferation) or 2 h (for Western blot).

Figure 4. Neurofibromin-mediated astrocyte survival operates in an
mTOR/GIT1-dependent manner. (A) Git1 knockdown using two independently generated mouse-specific RNAi (shGit1) lentiviruses reduces GIT1 expression in wild-type and Nf1-deficient (Nf1 −/−)
astrocytes. (B) shGit1 knockdown decreases Nf1 −/−, but not wildtype, astrocyte proliferation relative to (vector) controls. (C) shGit1
knockdown increases apoptosis (“% TUNEL+ cells”; arrows denote
TUNEL+ cells). (D) Proposed mechanism for GIT1-mediated neurofibromin/mTOR-regulated astrocyte survival. While neurofibromin inhibits AKT/mTOR/GIT1-mediated astrocyte growth (left panel),
neurofibromin loss leads to an AKT/mTOR-dependent reduction in
mTOR/GIT1 binding, which results in increased astrocyte survival
(middle panel). (Right panel) Genetic and pharmacological inhibition
of AKT, mTOR, or GIT1 reduces astrocyte survival. (∗ ) P < 0.05; (∗∗ )
P < 0.005; (∗∗∗ ) P < 0.0005.

wild-type pups dissociated in collagenase type I-A. All cells were serumstarved for 48 h prior to analysis, and neurofibromin loss was confirmed
by Western blot. 293T cells (3 × 106 cells) maintained in complete
DMEM were incubated in antibiotic-free DMEM 5 h prior to transfection.

Western blotting
Cells were lysed in 0.3% CHAPS buffer containing 40 mM HEPES (pH 7.4)
(Gibco), 2 mM EDTA, 10 mM sodium pyrophosphate, 10 mM β-glycerophosphate, and protease inhibitors. Western blots were performed as
described previously (Uhlmann et al. 2004) using primary antibodies (Supplemental Table S1) and horseradish peroxidase-conjugated affinitypurified secondary antibodies (1:5000; Cell Signaling Technology) by enhanced chemiluminescence-based detection (Pierce).

Immunoprecipitation
Precleared protein lysates (200–300 µg; 0.3% CHAPS buffer) were incubated for 16–18 h with primary antibodies (Supplemental Table S1) or normal

Cell proliferation
Astrocytes were serum-starved for 48 h and analyzed following 20 h of exposure to bromodeoxyuridine (BrdU) (Roche). Following the manufacturer’s instructions, fixed cells were incubated with peroxidase-conjugated
anti-BrdU antibodies and developed in tetramethyl-benzidine. Optical absorbance was measured at 450 nm using a microplate reader (Bio-Rad).

Apoptosis
Astrocytes were permeabilized in PBS containing 0.1% Triton X-100 and
0.1% sodium citrate. Apoptosis was detected using an in situ cell death
kit (Roche), with DNase included as positive control. Nuclei were counterstained with 0.005% bis-benzimide (Sigma). Images were captured using
a fluorescence microscope (Leica), and apoptotic cells were quantified by
direct cell counting using ImageJ.

Statistical analysis
All in vitro studies were repeated at least three times with comparable
results. Data were analyzed using parametric Student’s t-test or one-way
ANOVA in GraphPad Prism 5. Significance was set at P < 0.05.
Proteomic data will be deposited in Gene Expression Omnibus at the
time of publication.
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